Profil bibliographique

Ashraf Garrett

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

18Publications signalées

141Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

CAR-T cell therapy researchMultiple Myeloma Research and TreatmentsBiosimilars and Bioanalytical MethodsCutaneous lymphoproliferative disorders researchLymphoma Diagnosis and Treatment

Publications récentes

2026 articleOpenAlex

ABCL-853: Vispa-Cel, an Allogeneic Anti-CD19 CAR-T Therapy With a PD-1 Knockout, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER Phase 1 Clinical Trial)

Mohamad Cherry, Houston Holmes, James Essell, Ayad Hamdan et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

POSTER: ABCL-853: Vispa-Cel, an Allogeneic Anti-CD19 CAR-T Therapy With a PD-1 Knockout, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER Phase 1 Clinical Trial)

Mohamad Cherry, Houston Holmes, James Essell, Ayad Hamdan et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

Vispa-Cel, an Allogeneic Anti-CD19 CAR-T cell Therapy with a PD-1 Knockout, In Patients with relapsed/refractory B cell Non-Hodgkin Lymphoma (r/r B-NHL): Updated Results from the Antler Phase 1 Clinical Trial

Mehdi Hamadani, Houston Holmes, James Essell, Ayad Hamdan et autres

2 citationsTransplantation and Cellular Therapy

2026 articleOpenAlex

CB-011, an Allogeneic Anti-BCMA CAR-T cell Therapy with Immune Cloaking, for Patients with relapsed/refractory Multiple Myeloma (r/r MM): Dose Escalation Results from the Cammouflage Phase 1 Trial

Adriana Rossi, Luciano J. Costa, William B. Clark, Daniel Sherbenou et autres

2 citationsTransplantation and Cellular Therapy

2025 articleOpenAlex

A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CB-010, A NEXT-GENERATION CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, IN PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (GALLOP)

Winn Chatham, Salvatore Fiorenza, Julia Weinmann‐Menke, Olga Sánchez‐Pernaute et autres

0 citationsThe Journal of Rheumatology

Accès ouvert 2022 articleOpenAlex

Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

Tom Martin, Saad Z. Usmani, Jordan M. Schecter, Tito Roccia et autres

26 citationsCurrent Medical Research and Opinion

2022 reviewOpenAlex

Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

Luciano J. Costa, Parameswaran Hari, Jesús G. Berdeja, Valerio De Stefano et autres

7 citationsCurrent Medical Research and Opinion

2022 conference-abstractOpenAlex

EE437 Healthcare Resource Utilization and Costs in Patients with Multiple Myeloma Who Received 1 to 3 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and Exposed to (AND DISCONTINUED) Lenalidomide in the United States

Sundar Jagannath, Nuradh Joseph, E. Chinaeke, Concetta Crivera et autres

2 citationsValue in Health

Accès ouvert 2022 articleOpenAlex

Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma

Daanish Hoda, Robert H. Richards, Edward A. Faber, Abhinav Deol et autres

5 citationsFuture Oncology

Accès ouvert 2022 articleOpenAlex

Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States

Sundar Jagannath, N.R. Joseph, Jinghua He, Concetta Crivera et autres

14 citationsOncology and Therapy

Accès ouvert 2022 articleOpenAlex

Anakinra Targeting Cytokine Release Syndrome (CRS) Associated with Chimeric Antigen Receptor T Cell (CAR-T) Therapies

Sandy W. Wong, Shambavi Richard, Yi Lin, Deepu Madduri et autres

0 citationsTransplantation and Cellular Therapy

Accès ouvert 2022 reviewOpenAlex

Results from a Meta-Analysis of Ciltacabtagene Autoleucel Compared to Physician’s Choice in Patients with Relapsed or Refractory Multiple Myeloma

Parameswaran Hari, Jesús G. Berdeja, Valerio De Stefano, Francesca Gay et autres

0 citationsTransplantation and Cellular Therapy

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.